과제정보
연구 과제 주관 기관 : 산업통상자원부(MOTIE)
참고문헌
- Morton, N. M. : Obesity and corticosteroids: 11betahydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol. Cell Endocrinol. 316, 154 (2010). https://doi.org/10.1016/j.mce.2009.09.024
- Walker, B. R. and Andrew, R. : Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann. N. Y. Acad. Sci. 1083, 165 (2006). https://doi.org/10.1196/annals.1367.012
- Wamil, M. and Seckl, J. R. : Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov. Today 12, 504 (2007). https://doi.org/10.1016/j.drudis.2007.06.001
-
Hollis, G. and Huber, R. : 11
${\beta}$ -Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus. Diabetes Obes. Metab. 13, 1 (2011). -
Harno, E., Cottrell, E. C., Yu, A., DeSchoolmeester, J., Gutierrez, P. M., Denn, M., Swales, J. G., Goldberg, F. W., Bohlooly-Y, M., Andersen, H., Wild, M. J., Turnbull, A. V., Leighton, B. and White, A. : 11
${\beta}$ -Hydroxysteroid dehydrogenase type 1 (11${\beta}$ -HSD1) inhibitors still improve metabolic phenotype in male 11${\beta}$ -HSD1 knockout mice suggesting off-target mechanisms. Endocrinology 154, 4580 (2013). https://doi.org/10.1210/en.2013-1613 -
Wamil, M., Battle, J. H., Turban, S., Kipari, T., Seguret, D., de Sousa Peixoto, R., Nelson, Y. B., Nowakowska, D., Ferenbach, D., Ramage, L., Chapman, K. E., Hughes, J., Dunbar, D. R., Seckl, J. R. and Morton, N. M. : Novel fat depot-specific mechanisms underlie resistance to visceral obesity and inflammation in 11
${\beta}$ -hydroxysteroid dehydrogenase type 1- deficient mice. Diabetes 60, 1158 (2011). https://doi.org/10.2337/db10-0830 -
Park, J. S., Rhee, S. D., Kang, N. S., Jung, W. H., Kim, H. Y., Kim, J. H., Kang, S. K., Cheon, H. G., Ahn, J. H. and Kim, K. Y. : Anti-diabetic and anti-adipogenic effects of a novel selective 11
${\beta}$ -hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl- 1-phenylethanone (KR-66344). Biochem. Pharmacol. 81, 1028 (2011). https://doi.org/10.1016/j.bcp.2011.01.020 - Veniant, M. M., Hale, C., Hungate, R. W., Gahm, K., Emery, M. G., Jona, J., Joseph, S., Adams, J., Hague, A., Moniz, G., Zhang, J., Bartberger, M. D., Li, V., Syed, R., Jordan, S., Komorowski, R., Chen, M. M., Cupples, R., Kim, K. W., St. Jean, D. J. Jr., Johansson, L., Henriksson, M. A., Williams, M., Vallgarda, J., Fotsch, C. and Wang, M. : Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2- ((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5- methylthiazol-4(5H)-one (AMG 221). J. Med. Chem. 53, 4481 (2010). https://doi.org/10.1021/jm100242d
-
Park, J. S., Bae, S. J., Choi, S. W., Son, Y. H., Park, S. B., Rhee, S. D., Kim, H. Y., Jung, W. H., Kang, S. K., Ahn, J. H., Kim, S. H. and Kim, K. Y. : A novel 11
${\beta}$ -HSD1 inhibitor improves diabesity and osteoblast differentiation. J. Mol. Endocrinol. 52, 191 (2014). https://doi.org/10.1530/JME-13-0177 - Tiwari, A. : INCB-13739, an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for the treatment of type 2 diabetes. IDrugs 13, 266 (2010).
- Lin, J. H. and Lu, A. Y. : Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. 49, 403 (1997).
- 식품의약품안전청, 식품의약품안전평가원: 생명공학의약품의약동학 시험 가이드라인 (2010).
- Pacifici, G. M. and Viani, A. : Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences. Clin. Pharmacokinet. 23, 449 (1992). https://doi.org/10.2165/00003088-199223060-00005
피인용 문헌
- Thiamphenicol의 단일 경구투여에 따른 넙치와 조피볼락의 혈액내 잔류 분석 vol.28, pp.3, 2015, https://doi.org/10.13000/jfmse.2016.28.3.692